WallStSmart

Globus Medical (GMED)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 1073% more annual revenue ($36.36B vs $3.10B). GMED leads profitability with a 18.9% profit margin vs 13.2%. MDT appears more attractively valued with a PEG of 1.63. GMED earns a higher WallStSmart Score of 74/100 (B).

GMED

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 7.5Value: 7.3Quality: 9.5
Piotroski: 6/9Altman Z: 5.43

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GMEDUndervalued (+35.9%)

Margin of Safety

+35.9%

Fair Value

$137.63

Current Price

$80.26

$57.37 discount

UndervaluedFair: $137.63Overvalued
MDTUndervalued (+10.6%)

Margin of Safety

+10.6%

Fair Value

$91.75

Current Price

$87.54

$4.21 discount

UndervaluedFair: $91.75Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GMED6 strengths · Avg: 9.0/10
EPS GrowthGrowth
66.7%10/10

Earnings expanding 66.7% YoY

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.4310/10

Safe zone — low bankruptcy risk

P/E RatioValuation
18.0x8/10

Attractively priced relative to earnings

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
21.3%8/10

Strong operational efficiency at 21.3%

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$106.61B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

GMED1 concerns · Avg: 4.0/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.634/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : GMED

The strongest argument for GMED centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 18.9% and operating margin at 21.3%. Revenue growth of 27.0% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : GMED

The primary concerns for GMED are PEG Ratio.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

GMED profiles as a growth stock while MDT is a value play — different risk/reward profiles.

GMED carries more volatility with a beta of 0.95 — expect wider price swings.

GMED is growing revenue faster at 27.0% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

GMED scores higher overall (74/100 vs 62/100), backed by strong 18.9% margins and 27.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Globus Medical

HEALTHCARE · MEDICAL DEVICES · USA

Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?